Key result
In patients with primary mediastinal B-cell lymphoma, 2-year overall survival was 91% with DA-R-EPOCH and 89% with R-CHOP, with higher complete response rates for DA-R-EPOCH (84% vs 70%, P=0.046).
Why the study?
Does DA-R-EPOCH improve overall survival compared to R-CHOP in patients aged ≥18 years with primary mediastinal B-cell lymphoma?
Population
132 patients aged ≥18 years with primary mediastinal large B-cell lymphoma from 11 contributing centres
Comparison
Dose-adjusted R-EPOCH vs R-CHOP ± involved field radiation
Design
Cohort
Follow-up
2 years
Authors
Loading...
Similar survival supports either regimen in PMBCL; higher CR rates remain hypothesis-generating without randomized confirmation.
Cohort (n=132)
Yes
Does DA-R-EPOCH improve overall survival compared to R-CHOP in patients aged ≥18 years with primary mediastinal B-cell lymphoma?
Absolute Event Rate: 91% vs 89%
DA-R-EPOCH yields higher complete response rates but more toxicities compared to R-CHOP in primary mediastinal B-cell lymphoma, with similar 2-year overall survival.
Shah et al. (2017) conducted a cohort in Primary mediastinal B-cell lymphoma (n=132). DA-R-EPOCH vs. R-CHOP was evaluated on overall survival. In patients with primary mediastinal B-cell lymphoma, 2-year overall survival was 91% with DA-R-EPOCH and 89% with R-CHOP, with higher complete response rates for DA-R-EPOCH (84% vs 70%, P=0.046).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: